Recent Trends in Novel Drug Delivery System

AGENDA

8th-9th November, 2017
Location: Online

LifeScienceEvents

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK. Registered Office: 47 High Street, Barnet, Herts, EN5 5UW, UK

DESC

This event has CPD accreditation

www.

#

This is a draft agenda
The agenda will be finalised two weeks before the event

Contents

Day 1:

London GMT+1	New York EST	Tokyo JST		
			Middle Session	
13:15	09:15	21:15	**Session online**	**Speaker practice session Poster Viewing**
13:45	09:45	21:45	**Euroscicon Welcome**	*Euroscicon Host*
13:50	09:50	21:50	**Introduction by the chair**	
14:00	10:00	22:00	**Lipid-dendrimer nanohybrid systems for the smart delivery of anti-cancer drug combinations** **Q and A**	*Dr.Gigi N.C.CHIU, Ph.D, Professor, Assistant Head, Department of Pharmacy, National University , Singapore*
14:30	10:30	22:30	**Drug-delivery and Imaging Applications of Nanodiamonds** **Q and A**	Dr. Edward Kai-Hua Chow, Assistant Professor, National University of Singapore
15:00	11:00	23:00	**The use of microneedle in drug administration** **Q and A**	*Saif Aldeen AlRyalat,* MD, Doctor in Medicine, University of Jordon
15:30	11:30	23:30	**Novel lipidic and polymeric nanomedicines in cancer vaccination** **Q and A**	Dr. Sohail Akhter, Senior research fellow, Centre de Biophysique Moleculaire (CBM)
16:00	12:00	24:00	**The use of peptide-drug-conjugates for the reapplication of cancer drugs**	*Michael Firer,* Principal Investigator, Professor, Department of Chemical Engineering, Ariel University, Israel.
16:30	12:30	24:30	**Closing remarks, End of Session**	

Day 2:

London GMT+1	New York EST	Tokyo JST		
			Late Session	
09:15	05:15	17:15	**Session online**	**Speaker practice session Poster Viewing**
09:55	05:55	17:55	**Euroscicon Welcome**	*Euroscicon Host*
10:00	06:00	18:00	**Leading a Pathway for Early Pharmaceutical Researchers in the Preliminary development of NDDS** **Q and A**	*Dr. Selvasudha Nandakumar,* Puducherry campus, PRIST University, India.
10:30	06:30	18:30	**A polymeric conjugate platform for tumour-targeted delivery of insoluble drugs** **Q and A**	*Shyh-Dar Li,* Angiotech Professor in Drug Delivery, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada.
11:00	07:00	19:00	**Highly Deformable Vesicular Systems for Transdermal Delivery of NSAIDS** **Q and A**	*Dr. G. Praveen Kumar,* Principal and Professor, Department of Pharmaceutics, Sahasra Institute of Pharmaceutical Sciences, India
11:30	07:30	19:30	**Emerging Utility of Porphyrin-phospholipid Liposomes** **Q and A**	Dr. Jonathan Lovell, Associate Professor, State University of New York at Buffalo
12:30	08:00	20:30	**Closing remarks, End of Session**	

ABOUT THE SPEAKERS:

Gigi CHIU : Dr. Gigi Chiu obtained her B.Sc.(Pharm) and Ph.D. from the Faculty of Pharmaceutical Sciences, University of British Columbia, Canada. She completed her 2-year post-doctoral fellowship at the BC Cancer Research Center, and joined NUS Department of Pharmacy subsequently. Her research is focused on the design and development of various nanoscaled drug delivery platforms to improve the activity of therapeutic agents. These delivery platforms include 1) liposomes and lipid nanoparticles, 2) polymers and dendrimers, and 3) carbon-based nanomaterials, which are developed for applications in cancer therapy, modulation of drug transport and pharmacokinetics, and culturing of stem cells. Dr. Chiu has received research funding from various national agencies, including National Medical Research Council, Economic Development Board, and Agency for Science, Technology and Research (A*STAR). Dr. Chiu has published 50 research articles in the field of drug delivery and nanomedicine, and received the NUS Faculty of Science Young Scientist Award in 2012.

Shyh-Dar Li : Dr. Shyh-Dar Li received a BSc in Pharmacy from National Taiwan University and a PhD in Pharmaceutical Sciences from University of North Carolina at Chapel Hill. He is currently the Angiotech Professor in Drug Delivery at the Faculty of Pharmaceutical Sciences, University of British Columbia. His research focuses on developing innovative drug delivery technologies to enhance drug targeting with a particular interest in lipid and polymer based nanoparticles. His research program has been supported by federal funding including National Institutes of Health, Canadian Institutes of Health Research, and Natural Sciences and Engineering Research Council in Canada. In addition to contributing scholar publications in peer-reviewed journals, his team has successfully licensed four drug delivery technologies to industry with one in phase II trials for brain cancer therapy.

Gannu Praveen Kumar : Gannu Praveen Kumar, is currently working as Professor and Principal in Sahasra Institute of Pharmaceutical Sciences. He is an examiner for doctorate students and has guided 30 M. Pharm students. He has published in both National and International journals and compiled few chapters for text books. He received Gem of India award in the year 1999. He was selected as a best academician of Vaagdevi college of Pharmacy in 2002 and of Talla Padmavathi college of Pharmacy in 2011. Recently, he was appointed as an Inspector by Pharmacy council of India for the inspection of Pharmacy colleges. He is an advisor for Pharmaceutical Companies. He visited London, Dubai, Singapore, Malaysia, Spain and USA as invited speaker.

Michael Firer : Michael Firer is a Professor in the Dept. Chemical Engineering and Biotechnology and was department chair from 2010-2016. He also directed the Ariel Center for Applied Cancer Research. His research focuses on applied immunology and cancer cell biology, in particular developing Peptide-Drug Conjugates (PDCs) for targeted drug delivery

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK. Registered O
Herts, EN5 5UW, UK

to cancer cells several types of leukaemia, malignant Prostate Cancer and Small Cell lung Cancer or to disease associated lymphocytes. The laboratory has also developed a novel class of cancer drugs which are being developed in collaboration with a pharmaceutical partner.

Saif Aldeen AlRyalat : Saif Aldeen AlRyalat is a Doctor in Medicine from the University of Jordan. He ranked 3rd on the Kingdom of Jordan in the general secondary education exam 2011 with a GPA of 99.3%. He published more than 10 research articles in the last 2 years. He has more than 20 peer reviews for high impact journal. He is Organizer committee member and scientific committee member for several conferences and workshops. Also he is the Editorial Board Member at Journal of Systems and Integrative Neuroscience (JSIN), Advances in Psychology and Neuroscience (APN), and Scifed Journal of Neuroscience. Statistical analysis (on SPSS and ALE analysis). He received Certificate of excellence for promoting clinical research by The University of Jordan. He provided a patent for eczema treatment.

Nandakumar Selvasudha : Dr. N.Selvasudha received her B.Pharmacy and M.Pharmacy degree from DR.M.G.R Medical University, Tamilnadu, India. Recently (2017) she has completed her Ph.D., at PRIST University, India. She has published articles in reputed journal and written book. She has filed patent. She is active as potential reviewer and editorial board member. She has been awarded as woman scientist by Department of science and technology, Govt. of India and got official spotlight award for excellence in research. Her research interest is based on formulation of polymeric nanoparticulate drug delivery system, formulation and evaluation of natural agent based controlled drug delivery, drug delivery for cardiovascular diseases. She has passion to invent cost effective medicine which benefit society.

Jonathan Lovell: Dr .Jonathan F. Lovell is an Associate Professor of Biomedical Engineering at the State University of New York at Buffalo. Dr. Lovell's research interests focuses on developing clinically translatable nano platforms to address unmet clinical needs. Dr. Lovell has co-authored over 80 peer reviewed manuscripts. Dr. Lovell's work has been recognized with several awards including the NIH Early Independence Award (2013), the Biomedical Engineering Society Young Investigator Award (2015), and a NSF CAREER award (2016).

Sohail Akhter: Dr. Sohail Akhter is working as a senior fellow at Centre de Biophysique Moléculaire (CBM)-CNRS/ University of Orléans, UPR4301, Orléans, France. His present research focuses on the optimization of novel synthetic nano-biopharmaceuticals of nucleic acids for therapeutic vaccination against cancer. His past research experiences include Senior

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK. Registered O
Herts, EN5 5UW, UK

Postdoc research fellow at U.S. Food and Drug Administration (US-FDA)/The Centre for Drug Evaluation and Research (CDER)/DPQR, USA and research associate at the Department Pharmaceutics, Utrecht Institute of pharmaceutical sciences, Utrecht University, Netherlands. During his research career so far, he received many important awards including team excellence award-2015; U.S. Food and Drug Administration (US-FDA)/CDER/DPQR for this work on novel non-destructive chemometric method and PAT tools and Nanomedicine European technology platform fellowship in the year 2013. He has completed his PhD in Pharmaceutical Sciences (pharmaceutics and nanomedicine specialization). Dr. Akhter has authored more than 60 manuscripts in high impact journals and 10 book chapter in important Pharmaceutical/biomedical and nanomedicine related books. He is serving as the editorial board member and reviewer for many high impact journals, International journal of Pharmaceutics, Current Pharmaceutical design, current drug metabolism, Journal of controlled release are of few of them. His research interests involve development and characterization of nanomedicines, application of bio-materials in drug delivery & targeting, bio-pharmaceutics, drug/nanoparticles metabolism, bio-distribution and bio/pharmaceutical analysis.

Edward Kai-Hua Chow: Dr.Edward Kai-Hua Chow is an Assistant Professor at National University of Singapore (NUS) in the Cancer Science Institute of Singapore and the Department of Pharmacology. His research group is interested in understanding how specific genomic alterations affect cancer progression and how this information can be applied towards engineering-based approaches to improve combinatorial drug delivery and cancer imaging.

MEDIA SPONSORS



BENTHAM SCIENCE

TECHNOLOGY NETWORKS

laboratorynews

EuroSciCon Ltd. Registered in England and Wales, Company number: 4326921, Trading Address: Euroscicon Ltd, Highstone House, 165 High Street, Barnet, Herts. EN5 5SU, UK. Registered Office: 47 High Street, Barnet, Herts, EN5 5UW, UK